Photo taken from: Yüksel Ürün/X
Apr 2, 2024, 21:45
Yüksel Ürün: KEYNOTE-412 trial shows pembrolizumab + chemoradiotherapy doesn’t significantly improve event-free survival in unselected advanced head and neck squamous cell carcinoma vs placebo
Yüksel Ürün, Medical Oncologist at Ankara University, shared a post on X/Twitter:
“KEYNOTE-412 trial shows pembrolizumab + chemoradiotherapy doesn’t significantly improve event-free survival in unselected advanced head and neck squamous cell carcinoma vs placebo. More targeted approaches needed to enhance outcomes.”
Read further.
Source: Yüksel Ürün/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 23, 2025, 00:42
Feb 23, 2025, 00:31
Feb 22, 2025, 16:16
Feb 22, 2025, 16:04
Feb 22, 2025, 16:00
Feb 22, 2025, 15:54
Feb 22, 2025, 15:48
Feb 22, 2025, 15:33
Feb 22, 2025, 15:14
Feb 22, 2025, 15:04